Literature DB >> 24889127

Usefulness of (99m)Tc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients.

Maythinee Chantadisai1, Kanaungnit Kingpetch.   

Abstract

OBJECTIVE: The aim of the study was to evaluate the usefulness of (99m)Tc-pertechnetate whole body scan (WBS) with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer (DTC) patients.
METHODS: Fifty-six post total thyroidectomy patients were included. All patients were prospectively imaged with (99m)Tc-pertechnetate WBS with neck and chest SPECT/CT before (131)I ablation. The post-ablative (131)I WBS with SPECT/CT was performed at 5-7 days after receiving (131)I. Both scans were directly compared to determine the concordance of sites and number of remnant and metastasis.
RESULTS: Overall per-patient analysis, the percentage of concordance between two scans was 96.4%. In thyroid bed, lymph node, lung and bone subgroups, the percentage of concordance between two scans was 96.4, 92.9, 98.2 and 100%, respectively. All of them show good correlation with unweighted kappa between 0.7 and 1. Overall per-lesion analysis, the percentage of concordance between two scans was 84%. In thyroid bed, lymph node, lung and bone subgroups, the percentage of concordance between two scans was 89.5, 55, 82.6 and 50%, respectively.
CONCLUSIONS: Pre-ablative pertechnetate WBS with neck and chest SPECT/CT has good correlation for the detection of post-surgical thyroid remnant, cervical node and discrete lung nodule metastasis as compared to (131)I WBS with SPECT/CT per-patient basis. Because (131)I therapeutic activity is desired base on metastatic site and less concerning about the number of lesions, pre-ablative (99m)Tc-pertechnetate WBS with SPECT/CT was a good alternative tool to avoid radioiodine stunning in post-surgical DTC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24889127     DOI: 10.1007/s12149-014-0864-3

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  4 in total

1.  To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment.

Authors:  Murat Tuncel; Alexis Vrachimis; Alfredo Campenni; Bart de Keizer; Frederik A Verburg; Michael C Kreissl; Petra Petranovic Ovcaricek; Tamara Geliashvili; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08       Impact factor: 10.057

2.  99mTc-pertechnetate-avid metastases from differentiated thyroid cancer are prone to benefit from 131I therapy: A prospective observational study.

Authors:  Min Liu; Li Chai; Qiong Luo; Maomei Ruan; Lingxiao Cheng; Zhongwei Lv; Libo Chen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

3.  Hyperthyroidism secondary to disseminated differentiated thyroid cancer on 99mTcO4 scan.

Authors:  Yan Hu; Hong-Yan Yin; Guo-Bing Liu; Yan Xiu; Hong-Cheng Shi
Journal:  Chin Med J (Engl)       Date:  2019-10-05       Impact factor: 2.628

4.  Can the function of the tubarial glands be evaluated using [99mTc]pertechnetate SPECT/CT, [18F]FDG PET/CT, and [11C]methionine PET/CT?

Authors:  Yohji Matsusaka; Tomohiko Yamane; Kenji Fukushima; Akira Seto; Ichiro Matsunari; Ichiei Kuji
Journal:  EJNMMI Res       Date:  2021-03-31       Impact factor: 3.138

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.